Olaparib is a medication used in this clinical trial as a maintenance therapy for patients who have been newly diagnosed with advanced ovarian, fallopian tube, or primitive peritoneal cancer. It is specifically for patients who do not have a BRCA gene mutation. The role of Olaparib in this trial is to help prevent the cancer from coming back after the initial treatment. It works by blocking certain enzymes in the cancer cells, which can help stop the cancer from growing and spreading. This medication is taken orally, meaning it is swallowed in the form of a pill. The trial aims to see how effective Olaparib is in keeping the cancer from progressing and to understand more about how different patient and tumor characteristics might affect the treatment’s success.

BRCA wild-type advanced ovarian, fallopian tube, and primary peritoneal cancer – This disease involves the growth of cancerous cells in the ovaries, fallopian tubes, or the lining of the abdominal cavity, known as the peritoneum. It is characterized by the absence of mutations in the BRCA genes, which are often linked to hereditary breast and ovarian cancers. The cancer typically progresses by spreading from the original site to nearby tissues and organs. As it advances, it may cause symptoms such as abdominal bloating, pain, and changes in bowel habits. The disease can also lead to the accumulation of fluid in the abdomen, known as ascites. Over time, it may spread to distant organs, complicating the condition further.